tirzepatide phase 1 Efficacy of tirzepatide in phase

72% male) from 804 sites in 41 countries with overweight or obesity (BMI of 27 kg/m or higher) who were enrolled and treated with weekly injections of semaglutide (at doses slowly titrated to 2.4 mg at week 16) or placebo

Nunes NS, Chandran P, Sundby M, Visioli F, da Costa Goncalves F, Burks SR, et al

2024 NEJM) actually showed a slower decline in eGFR over time on semaglutide in people with CKD and type 2 diabetes, a 24 percent relative reduction in kidney failure and cardiovascular death

Many patients at SkinSio Clinics pair their semaglutide program with Non Surgical Fat Reduction for stubborn localised fat, or RF Skin Tightening to address loose skin as weight comes off